0.829
IF
20
MNiSW
166.26
ICV
RESEARCH PAPER
 
CC BY-NC-ND 3.0
 
 

The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment

Marek Bieńko 1  ,  
 
1
Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences, Lublin, Poland
Ann Agric Environ Med 2017;24(3):446–452
KEYWORDS:
ABSTRACT:
Introduction:
This study evaluates the effects of three different doses of chromium sulphate on bone density and the tomographic parameters of skeletal tissue of rats.

Material and Methods:
The experiment was performed on 40 male Wistar rats which received, by gavage, during 90 days, a chromium sulphate in either a daily dose of 400, 600 or 800 µg/kg BW. At the end of experiment, the rats were scanned using the densitometry method (DXA) to determine the bone mineral density, bone mineral content of total skeleton and vertebral column (L2-L4) and parameters of body composition (Lean Mass and Fat Mass). The isolated femora were scanned using peripheral a quantitative computed tomography method (pQCT) for a separate analysis of the trabecular and cortical bone tissue. The ultimate strength, work to ultimate and the Young modulus of femora was also investigated by the three-point bending test.

Results:
The negative impact of chromium was observed in relation to bone tissue. All doses significantly decreased total skeleton density and mineral content, and also had impact upon the isolated femora and vertebral column. Trabecular volumetric bone mineral density and trabecular bone mineral content measured by pQCT in distal femur metaphysis were significantly lower in the experimental groups than in the control. Higher doses of chromium also significantly decreased values of ultimate strength and Young modulus in the investigated femora.

Conclusions:
The results of the experiment demonstrate that chromium sulphate is dose dependent, and exerts a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

CORRESPONDING AUTHOR:
Marek Bieńko   
Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences, Lublin, Poland
 
REFERENCES (53):
1. Assem L, Zhu H. Chromium. Toxicological overview. Institute of Environment and Health, Cranfield University. 2007. 1–14.
2. Witmer CM, Harris R, Shupack SI. Oral bioavailability of chromium from a specific site. Environ Health Perspect. 1991; 92: 105–110.
3. Tipton IH. The distribution of trace metals in the human body. Metal-Binding in Medicine. Philadelphia: J. B. Lippincott Co; 1960.
4. Andrews RE, Shah KM, Wilkinson JM, Gartland A. Effects of cobalt and chromium ions at clinically equivalent concentrations after metal-on-metal hip replacement on human osteoblasts and osteoclasts: implications for skeletal health. Bone. 2011; 49(4): 717–723.
5. Junaid M, Murthy RC, Saxena DK. Embryo- and fetotoxicity of chromium in pregestationally exposed mice. Bull Environ Contam Toxicol. 1996; 57(2): 327–334.
6. Junaid M, Murthy RC, Saxena DK. Embryotoxicity of orally administered chromium in mice: exposure during the period of organogenesis. Toxicol Lett. 1996; 84(3): 143–148.
7. Kanojia RK, Junaid M, Murthy RC. Chromium induced teratogenicity in female rat. Toxicol Lett. 1996; 89(3): 207–213.
8. Sankaramanivel S, Jeyapriya R, Hemalatha D, Djody S, Arunakaran J, Srinivasan N. Effect of chromium on vertebrae, femur and calvaria of adult male rats. Hum Exp Toxicol. 2006; 25(6): 311–318.
9. Gasser JA. Bone measurements by peripheral quantitative computed tomography in rodents. Methods Mol Med. 2003; 80: 323–341.
10. McCarty MF. Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. Med Hypotheses. 1995; 45(3): 241–246.
11. Sreejayan N, Marone PA, Lau FC, Yasmin T, Bagchi M, Bagchi D. Safety and toxicological evaluation of a novel chromium(III) dinicocysteinate complex. Toxicol Mech Methods. 2010; 20(6): 321–333.
12. De Lucca RC, Dutrey PL, Villarino ME, Ubios AM. Effect of different doses of hexavalent chromium on mandibular growth and tooth eruption in juvenile Wistar rats. Exp Toxicol Pathol. 2009; 61(4):347–352.
13. Soudani N, Ben A, I, Troudi A, Bouaziz H, Boudawara T, Zeghal N. Oxidative stress induced by chromium (VI) in bone of suckling rats. Toxicology and Industrial Health. 2011; 27(8): 724–7.
14. Radzki RP, Bieńko M, Pierzynowski SG. Anti-osteopenic effect of alpha-ketoglutarate sodium salt in ovariectomized rats. J Bone Miner Metab. 2012; 30(6): 651–659.
15. Radzki RP, Bieńko M, Wolski D, Lis A, Radzka A. Lipoic acid dose-dependently stimulates bone formation in ovariectomized rats. Can J PhysiolPharmacol. 2016; 94(9): 947–954.
16. De Smet K, De Haan R, Calistri A, Campbell PA, Ebramzadeh E, Pattyn C et al. Metal ion measurement as a diagnostic tool to identify problems with metal-on-metal hip resurfacing. J Bone Joint Surg Am. 2008; 90 Suppl 4: 202–208.
17. Little CP, Ruiz AL, Harding IJ, McLardy-Smith P, Gundle R, Murray DW, et al. Osteonecrosis in retrieved femoral heads after failed resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2005; 87(3): 320–323.
18. Beaupied H, Lespessailles E, Benhamou CL. Evaluation of macro-structural bone biomechanics. Joint Bone Spine. 2007; 74(3): 233–239.
19. Kanojia RK, Junaid M, Murthy RC. Embryo and fetotoxicity of hexavalent chromium: a long-term study. Toxicol Lett. 1998; 95(3): 165–172.
20. Bagchi D, Stohs SJ, Downs BW, Bagchi M, Preuss HG. Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology. 2002; 180(1): 5–22.
21. Schreck R, Baeuerle PA. A role for oxygen radicals as second messengers. Trends Cell Biol. 1991; 1(2–3): 39–42.
22. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991; 10(8): 2247–2258.
23. Vega D, Maalouf NM, Sakhaee K. Clinical Review: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007; 92(12): 4514–4521.
24. Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem. 2007; 295(1–2): 45–52.
25. Radzki RP, Bieńko M, Filip R, Albera E, Kankofer M. Effect of Strontium Ranelate on Femur Densitometry and Antioxidative/Oxidative Status in Castrated Male Rats. Scand J Lab Anim Sci. 2009; 36(2): 193–201.
26. Bailey MM, Boohaker JG, Sawyer RD, Behling JE, Rasco JF, Jernigan JJ, et al. Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring. Birth Defects Res B Dev Reprod Toxicol. 2006; 77(3): 244–249.
27. Ramajayam G, Sridhar M, Karthikeyan S, Lavanya R, Veni S, Vignesh RC, et al. Effects of Aroclor 1254 on femoral bone metabolism in adult male Wistar rats. Toxicology. 2007; 241(3): 99–105.
28. Di Bona KR, Love S, Rhodes NR, McAdory D, Sinha SH, Kern N, et al. Chromium is not an essential trace element for mammals: effects of a “low-chromium” diet. J Biol Inorg Chem. 2011; 16(3): 381–390.
29. Levina A, Lay PA. Chemical properties and toxicity of chromium(III) nutritional supplements. Chem Res Toxicol. 2008; 21(3): 563–571.
30. Lewicki S, Zdanowski R, Krzyzowska M, Lewicka A, Debski B, Niemcewicz M, et al. The role of Chromium III in the organism and its possible use in diabetes and obesity treatment. Ann Agric Environ Med. 2014; 21(2): 331–335.
31. Lukaski HC. Chromium as a supplement. Annu Rev Nutr. 1999; 19: 279–302.
32. Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc. 2004; 63(1): 41–47.
33. Gomes MR, Rogero MM, Tirapegui J. Considerations about chromium, insulin and physical exercise. Rev Bras Med Esporte. 2015; 11(5): 246e–250e.
34. Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD. Chromium picolinate toxicity. Ann Pharmacother. 1998; 32(4): 428–431.
35. Onakpoya I, Posadzki P, Ernst E. Chromium supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. Obes Rev. 2013; 14(6): 496–507.
36. Anton SD, Morrison CD, Cefalu WT, Martin CK, Coulon S, Geiselman P, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther. 2008; 10(5): 405–412.
37. McLeod MN, Golden RN. Chromium treatment of depression. Int J Neuropsychopharmacol. 2000; 3(4): 311–314.
38. Zha LY, Wang MQ, Xu ZR, Gu LY. Efficacy of chromium(III) supplementation on growth, body composition, serum parameters, and tissue chromium in rats. Biol Trace Elem Res. 2007; 119(1): 42–50.
39. Shara M, Kincaid AE, Limpach AL, Sandstrom R, Barrett L, Norton N, et al. Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex. J Inorg Biochem. 2007; 101(7): 1059–1069.
40. Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr. 2001; 20(4): 293–306.
41. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res. 1989; 11: 163–180.
42. Hallmark MA, Reynolds TH, DeSouza CA, Dotson CO, Anderson RA, Rogers MA. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc. 1996; 28(1): 139–144.
43. Bahadori B, Wallner S, Schneider H, Wascher TC, Toplak H. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet. Acta Med Austriaca. 1997; 24(5): 185–187.
44. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab. 1999; 1(6): 331–337.
45. Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc. 1997; 29(8): 992–998.
46. Sun C, Zhang W, Wang S, Zhang Y. Effect of chromium gluconate on body weight, serum leptin and insulin in rats. Wei Sheng Yan Jiu. 2000; 29(6): 370–371.
47. Bennett R, Adams B, French A, Neggers Y, Vincent JB. High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. Biol Trace Elem Res. 2006; 113(1): 53–66.
48. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004; 79(4): 529–536.
49. McAdory D, Rhodes NR, Briggins F, Bailey MM, Di Bona KR, Goodwin C, et al. Potential of chromium(III) picolinate for reproductive or developmental toxicity following exposure of male CD-1 mice prior to mating. Biol Trace Elem Res. 2011; 143(3): 1666–1672.
50. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998; 17(6): 548–555.
51. Vincent JB. Mechanisms of chromium action: low-molecular-weight chromium-binding substance. J Am Coll Nutr. 1999; 18(1): 6–12.
52. Attenburrow MJ, Odontiadis J, Murray BJ, Cowen PJ, Franklin M. Chromium treatment decreases the sensitivity of 5-HT2A receptors. Psychopharmacology (Berl). 2002; 159(4): 432–436.
53. Onakpoya IJ, Wider B, Pittler MH, Ernst E. Food supplements for body weight reduction: a systematic review of systematic reviews. Obesity (Silver Spring). 2011; 19(2): 239–244.
eISSN:1898-2263
ISSN:1232-1966